Status:
RECRUITING
Urothelial Cancer Screening in Individuals With Lynch Syndrome Using a Urine Tumor DNA Panel (LS-URO Study)
Lead Sponsor:
Tampere University Hospital
Collaborating Sponsors:
Tampere University
Conditions:
Urothelial Carcinoma
Lynch Syndrome
Eligibility:
All Genders
50-75 years
Phase:
NA
Brief Summary
Lynch syndrome (LS) is an inherited cancer predisposition syndrome caused by pathogenic germline variants in DNA mismatch repair (MMR) genes. New cancer screening and diagnostic tools are urgently nee...
Eligibility Criteria
Inclusion
- Willing and able to provide informed consent
- Diagnosis of Lynch syndrome
- Age 50 - 75 years at study recruitment
Exclusion
- Concurrent urothelial carcinoma
Key Trial Info
Start Date :
April 10 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2034
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06218433
Start Date
April 10 2023
End Date
December 31 2034
Last Update
November 18 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Vancouver Prostate Centre
Vancouver, Canada
2
Tampere University Hospital and Tampere University
Tampere, Finland